MCID: GLM045
MIFTS: 59

Glioma

Categories: Rare diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Glioma

MalaCards integrated aliases for Glioma:

Name: Glioma 50 29 52 69

Classifications:



Summaries for Glioma

NIH Rare Diseases : 50 glioma refers to a type of brain tumor that develops from the glial cells, which are specialized cells that surround and support neurons (nerve cells) in the brain. it is generally classified based on which type of glial cell is involved in the tumor: astocytoma - tumors that develop from star-shaped glial cells called astrocytes ependymomas - tumors that arise from ependymal cells that line the ventricles of the brain and the center of the spinal cord oligodendrogliomas - tumors that affect the oligodendrocytes the symptoms of glioma vary by type but may include headaches; nausea and vomiting; confusion; personality changes; trouble with balance; vision problems; speech difficulties; and/or seizures. the exact underlying cause is unknown. in most cases, the tumor occurs sporadically in people with no family history of the condition. treatment depends on many factors, including the type, size, stage and location of the tumor, but may include surgery, radiation therapy, chemotherapy and/or targeted therapy. last updated: 7/15/2015

MalaCards based summary : Glioma is related to spinal cord glioma and mixed oligodendroglioma-astrocytoma. An important gene associated with Glioma is LGI1 (Leucine Rich Glioma Inactivated 1), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Dacarbazine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial, and related phenotypes are Decreased viability and cellular

Wikipedia : 72 A glioma is a type of tumor that starts in the brain or spine. It is called a glioma because it arises... more...

Related Diseases for Glioma

Diseases in the Glioma family:

Malignant Glioma

Diseases related to Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 408)
id Related Disease Score Top Affiliating Genes
1 spinal cord glioma 33.7 EGFR IDH1 IDH2 POT1 PTEN TP53
2 mixed oligodendroglioma-astrocytoma 32.5 IDH1 IDH2 TP53
3 lymphopenia 30.7 EGFR IDH1 MDM2 PTEN TP53
4 measles 30.3 BAX EGFR ERBB2
5 dysembryoplastic neuroepithelial tumor 30.2 EGFR ERBB2 TP53
6 bardet-biedl syndrome 29.8 CCND1 EGFR ERBB2 MMP2 PTEN TP53
7 nasopharyngeal carcinoma 29.7 BAX EGFR IDH1 MDM2 PTEN TP53
8 hepatocellular carcinoma 29.6 BAX CCND1 MDM2 MMP2 PTEN TP53
9 lung cancer 28.8 BAX CCND1 CDK6 EGFR ERBB2 MDM2
10 prostate cancer 28.6 AKT3 BAX CCND1 EGFR ERBB2 GLIPR1
11 optic nerve glioma 12.2
12 glioma susceptibility 1 12.1
13 childhood brain stem glioma 12.1
14 diffuse intrinsic pontine glioma 12.1
15 brain stem glioma 12.1
16 malignant glioma 12.1
17 optic pathway glioma 12.1
18 glioma susceptibility 2 12.0
19 glioma susceptibility 9 12.0
20 brain glioma 11.9
21 mixed glioma 11.9
22 chordoid glioma 11.9
23 third ventricle chordoid glioma 11.9
24 subependymal glioma 11.9
25 childhood optic nerve glioma 11.8
26 angiocentric glioma 11.8
27 glioma susceptibility 8 11.7
28 glioma susceptibility 7 11.7
29 glioma susceptibility 5 11.7
30 glioma susceptibility 4 11.7
31 glioma susceptibility 6 11.7
32 adult brainstem mixed glioma 11.7
33 adult brain stem glioma 11.6
34 visual pathway and hypothalamic glioma, childhood 11.6
35 glioblastoma 3 11.4
36 mismatch repair cancer syndrome 11.4
37 astrocytoma 11.2
38 retinoblastoma 11.1
39 neurofibromatosis, type 1 11.1
40 optic disk drusen 11.1 IDH1 IDH2
41 oligodendroglioma 11.1
42 gliosarcoma 11.0
43 pituicytoma 11.0
44 oligoastrocytoma 11.0
45 encephalocraniocutaneous lipomatosis 11.0
46 autoimmune encephalitis 11.0
47 infiltrating ureter transitional cell carcinoma 11.0 EGFR ERBB2
48 early myoclonic encephalopathy 11.0 IDH1 IDH2 PTEN
49 nasal glial heterotopia 11.0
50 rnase t2-deficient leukoencephalopathy 11.0 MDM2 TP53

Graphical network of the top 20 diseases related to Glioma:



Diseases related to Glioma

Symptoms & Phenotypes for Glioma

GenomeRNAi Phenotypes related to Glioma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.32 EGFR
2 Decreased viability GR00107-A-1 10.32 PRKCA
3 Decreased viability GR00221-A-1 10.32 CDK6 POT1 EGFR AKT3 PRKCA
4 Decreased viability GR00221-A-2 10.32 CDK6 AKT3 PRKCA
5 Decreased viability GR00221-A-3 10.32 POT1 AKT3 ERBB2
6 Decreased viability GR00221-A-4 10.32 CDK6 POT1 EGFR AKT3 ERBB2 PRKCA
7 Decreased viability GR00301-A 10.32 AKT3 CDK6
8 Decreased viability GR00342-S-1 10.32 PRKCA
9 Decreased viability GR00342-S-2 10.32 PRKCA
10 Decreased viability GR00342-S-3 10.32 PRKCA
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 10.11 CDK6
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 10.11 CDK6 ERBB2
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 10.11 CDK6
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-206 10.11 POT1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 10.11 POT1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.11 POT1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.11 MAGED4B CDK6 POT1 AKT3 ERBB2
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-61 10.11 CDK6
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 10.11 POT1
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-87 10.11 ERBB2
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 10.11 CDK6 AKT3
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-94 10.11 MAGED4B
23 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.65 ERBB2 EGFR AKT3 PTEN PRKCA
24 Increased cell viability after pRB stimulation GR00230-A-1 8.92 ERBB2 EGFR AKT3 PRKCA

MGI Mouse Phenotypes related to Glioma:

44 (show all 16)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.39 CDK6 BAX DMBT1 CCND1 AKT3 MDM2
2 cardiovascular system MP:0005385 10.34 CDK6 ACSL5 CCND1 AKT3 MDM2 ERBB2
3 growth/size/body region MP:0005378 10.34 BAX CDK6 CCND1 AKT3 LGI1 MDM2
4 mortality/aging MP:0010768 10.33 BAX CDK6 CCND1 AKT3 LGI1 MDM2
5 homeostasis/metabolism MP:0005376 10.31 AKT3 BAX ACSL5 CCND1 EGFR DMBT1
6 hematopoietic system MP:0005397 10.25 CCND1 AKT3 CDK6 BAX ACSL5 EGFR
7 neoplasm MP:0002006 10.25 CDK6 BAX DMBT1 CCND1 AKT3 MDM2
8 endocrine/exocrine gland MP:0005379 10.24 CDK6 BAX CCND1 AKT3 ERBB2 EGFR
9 immune system MP:0005387 10.22 CCND1 AKT3 CDK6 BAX EGFR DMBT1
10 nervous system MP:0003631 10.15 BAX CCND1 AKT3 LGI1 MDM2 ERBB2
11 muscle MP:0005369 10.09 BAX CDK6 MDM2 ERBB2 EGFR TP53
12 reproductive system MP:0005389 9.96 BAX CDK6 CCND1 AKT3 MDM2 ERBB2
13 respiratory system MP:0005388 9.76 BAX CCND1 EGFR ERBB2 IDH1 MMP2
14 pigmentation MP:0001186 9.72 LGI1 EGFR PTEN MDM2 TP53
15 skeleton MP:0005390 9.65 BAX ACSL5 CCND1 MDM2 ERBB2 IDH1
16 vision/eye MP:0005391 9.23 CCND1 BAX ACSL5 LGI1 EGFR MMP2

Drugs & Therapeutics for Glioma

Drugs for Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 658)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
6
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1 33419-42-0 36462
7
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
8
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
9 Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
10
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
11
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
12
Mesna Approved Phase 4,Phase 3,Phase 2,Phase 1 3375-50-6 598
13 Piracetam Approved Phase 4,Phase 2 7491-74-9
14
Valproic Acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 99-66-1 3121
15
Benzocaine Approved Phase 4,Phase 3,Phase 2,Early Phase 1 1994-09-7, 94-09-7 2337
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
17
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
18
Glutamic Acid Approved, Nutraceutical Phase 4 56-86-0 33032
19 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Early Phase 1
20 Etiracetam Investigational Phase 4,Phase 1,Phase 2 33996-58-6
21 Anticonvulsants Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
22 Nootropic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
25 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1
32 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1
33 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
35 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1
37 Protective Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
38 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Phase 1
39 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1
40 Anti-Anxiety Agents Phase 4,Phase 2
41 Antimanic Agents Phase 4,Phase 2,Phase 3,Phase 1
42 GABA Agents Phase 4,Phase 2,Phase 3,Phase 1
43 Neuroprotective Agents Phase 4,Phase 2,Phase 1
44 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1
46 Tranquilizing Agents Phase 4,Phase 2,Phase 3,Phase 1
47 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
48 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
49
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
50
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690

Interventional clinical trials:

(show top 50) (show all 1943)

id Name Status NCT ID Phase Drugs
1 Correlation Between SV2A Expression in Tumour Tissue and Efficacy of Levetiracetam in Glioma Patients With Epilepsy Unknown status NCT00454935 Phase 4
2 Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
3 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4 Temozolomide
4 Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy Recruiting NCT02193568 Phase 4
5 HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Recruiting NCT02875314 Phase 4 Induction;Single Cycle Intensive Chemotherapy;Tandem 3 Cycle Intensive Chemotherapy
6 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Recruiting NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
7 Seizure Treatment in Glioma Not yet recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
8 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
9 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Not yet recruiting NCT03297125 Phase 4
10 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
11 Cognitive Rehabilitation of Glioma Patients Unknown status NCT00256425 Phase 3
12 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
13 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
14 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
15 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
16 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
17 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
18 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
19 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
20 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
21 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
22 Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma Unknown status NCT00053872 Phase 3 cisplatin;lomustine;vincristine sulfate
23 Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children Unknown status NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;etoposide;trofosfamide/etoposide
24 Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
25 Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas Completed NCT01167322 Phase 3 NPC-07 for oral administration
26 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
27 Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children Completed NCT01635140 Phase 3
28 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3 temozolomide
29 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
30 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
31 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
32 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
33 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
34 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
35 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
36 Radiation Therapy in Treating Patients With Brain Cancer Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
37 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
38 Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients Completed NCT00135876 Phase 3 dalteparin
39 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
40 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3 Chloroquine
41 Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
42 Combination Chemotherapy in Treating Children With Progressive Brain Tumors Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
43 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
44 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
45 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
46 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
47 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
48 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3 Temozolomide
49 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3 Temozolomide;Semustine
50 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea

Search NIH Clinical Center for Glioma

Genetic Tests for Glioma

Genetic tests related to Glioma:

id Genetic test Affiliating Genes
1 Glioma 29

Anatomical Context for Glioma

MalaCards organs/tissues related to Glioma:

39
Brain, T Cells, Endothelial, Spinal Cord, Bone, Testes, Bone Marrow

Publications for Glioma

Articles related to Glioma:

(show top 50) (show all 6601)
id Title Authors Year
1
miR-320a functions as a suppressor for gliomas by targeting SND1 and I^-catenin, and predicts the prognosis of patients. ( 28160566 )
2017
2
IDH1-Mutation in Diffuse Gliomas in Persons Age 55 Years and Over. ( 28110298 )
2017
3
The Unwanted Cell Migration in the Brain: Glioma Metastasis. ( 28478595 )
2017
4
HP1I+ is highly expressed in glioma cells and facilitates cell proliferation and survival. ( 28623138 )
2017
5
Chordoid Glioma: A Neoplasm Found in the Anterior Part of the Third Ventricle. ( 28708638 )
2017
6
C-type natriuretic peptide-modified lipid vesicles: fabrication and use for the treatment of brain glioma. ( 28402948 )
2017
7
Additional evidence supports association of common genetic variants in VTI1A and ETFA with increased risk of glioma susceptibility. ( 28320150 )
2017
8
Targeting CDK7 or BRD4 Blocks Diffuse Intrinsic Pontine Glioma Growth. ( 28455397 )
2017
9
ARID4B is a good biomarker to predict tumour behaviour and decide WHO grades in gliomas and meningiomas. ( 27451434 )
2017
10
Silencing of Forkhead box D1 inhibits proliferation and migration in glioma cells. ( 28075458 )
2017
11
Forkhead box P3 regulates ARHGAP15 expression and affects migration of glioma cells through the Rac1 signaling pathway. ( 27862679 )
2017
12
Predictive therapeutic planning for irreversible electroporation treatment of spontaneous malignant glioma. ( 28594449 )
2017
13
Development of a novel imaging agent using peptide-coated gold nanoparticles toward brain glioma stem cell marker CD133. ( 27721007 )
2017
14
MiR-592 functions as a tumor suppressor in glioma by targeting IGFBP2. ( 28718372 )
2017
15
DNA methylation-mediated caspase-8 downregulation is associated with anti-apoptotic activity and human malignant glioma grade. ( 28204824 )
2017
16
Deceptive morphologic and epigenetic heterogeneity in diffuse intrinsic pontine glioma. ( 28947983 )
2017
17
Experimental study of a novel tumstatin on C6 brain glioma in vitro. ( 28928823 )
2017
18
Dying glioma cells establish a proangiogenic microenvironment through a caspase 3 dependent mechanism. ( 27826040 )
2017
19
Lipoprotein lipase and phospholipid transfer protein overexpression in human glioma cells and their effect on cell growth, apoptosis, and migration. ( 27864281 )
2017
20
Inhibition of the Hedgehog signaling pathway suppresses cell proliferation by regulating the Gli2/miR-124/AURKA axis in human glioma cells. ( 28393219 )
2017
21
Long noncoding RNA papillary thyroid carcinoma susceptibility candidate 3 (PTCSC3) inhibits proliferation and invasion of glioma cells by suppressing the Wnt/I^-catenin signaling pathway. ( 28187755 )
2017
22
Positron emission tomography imaging in diffuse intrinsic pontine glioma. ( 28856152 )
2017
23
Evaluation of rat C6 malignant glioma using spectral computed tomography. ( 28810555 )
2017
24
Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo-/radio-therapy for glioma. ( 28088075 )
2017
25
MiR-1202 functions as a tumor suppressor in glioma cells by targeting Rab1A. ( 28443461 )
2017
26
Expression and prognostic role of orphan receptor GPR110 in glioma. ( 28728843 )
2017
27
Overexpression of ILK promotes temozolomide resistance in glioma cells. ( 28138714 )
2017
28
The lncRNA UCA1 interacts with miR-182 to modulate glioma proliferation and migration by targeting iASPP. ( 28137422 )
2017
29
Clinical Presentation and Outcome of Patients With Optic Pathway Glioma. ( 28847625 )
2017
30
MicroRNA-520c inhibits glioma cell migration and invasion by the suppression of transforming growth factor-I^ receptor typeA 2. ( 28184932 )
2017
31
Elevated IQGAP1 and CDC42 levels correlate with tumor malignancy of human glioma. ( 28035419 )
2017
32
Tweety-Homolog 1 Drives Brain Colonization of Gliomas. ( 28607172 )
2017
33
High expression of Bruton's tyrosine kinase (BTK) is required for EGFR-induced NF-I_B activation and predicts poor prognosis in human glioma. ( 28946903 )
2017
34
Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status. ( 28091987 )
2017
35
Culture methods of diffuse intrinsic pontine glioma cells determine response to targeted therapies. ( 28947132 )
2017
36
Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma. ( 28583810 )
2017
37
Reduced Expression of Jumonji AT-Rich Interactive Domain 2 (JARID2) in Glioma Inhibits Tumor Growth In Vitro and In Vivo. ( 27641964 )
2017
38
A new diagnostic marker for differentiating multicentric gliomas from multiple intracranial diffuse large B-cell lymphomas on 18F-FDG PET images. ( 28796066 )
2017
39
A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. ( 28748343 )
2017
40
Overexpression of interleukin-33 is associated with poor prognosis of patients with glioma. ( 27050560 )
2017
41
MicroRNA-361-5p inhibits epithelial-to-mesenchymal transition of glioma cells through targeting Twist1. ( 28184914 )
2017
42
Upregulation of long noncoding RNA zinc finger antisense 1 enhances epithelial-mesenchymal transition in vitro and predicts poor prognosis in glioma. ( 28349823 )
2017
43
Epigenetic silencing and activation of transcription: influence on the radiation sensitivity of glioma cell lines. ( 28044469 )
2017
44
Optic pathway glioma of childhood. ( 28257299 )
2017
45
Optic Pathway Gliomas Secondary to Neurofibromatosis Type 1. ( 28941532 )
2017
46
Overexpression of SCUBE2 Inhibits Proliferation, Migration, and Invasion in Glioma Cells. ( 27697090 )
2017
47
Intra-individual comparison of different gadolinium-based contrast agents in the quantitative evaluation of C6 glioma with dynamic contrast-enhanced magnetic resonance imaging. ( 28078511 )
2017
48
Targeting effect of microRNA on CD133 and its impact analysis on proliferation and invasion of glioma cells. ( 28362995 )
2017
49
Spontaneous complete regression of a brain stem glioma pathologically diagnosed as a high-grade glioma. ( 28808781 )
2017
50
Anaesthetic management for awake craniotomy in brain glioma resection: initial experience in Military Hospital Mohamed V of Rabat. ( 28904684 )
2017

Variations for Glioma

Cosmic variations for Glioma:

9 (show top 50) (show all 2211)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM40802 ZW10 central nervous system,brain,glioma,NS c.2140C>T p.P714S 7
2 COSM40801 ZSWIM4 central nervous system,brain,glioma,NS c.266C>T p.P89L 7
3 COSM39611 ZPLD1 central nervous system,brain,glioma,NS c.393A>T p.G131G 7
4 COSM40237 ZNF687 central nervous system,brain,glioma,NS c.3651C>T p.T1217T 7
5 COSM39318 ZNF687 central nervous system,brain,glioma,NS c.2044T>A p.C682S 7
6 COSM39317 ZNF687 central nervous system,brain,glioma,NS c.2043G>C p.Q681H 7
7 COSM39149 ZNF507 central nervous system,brain,glioma,NS c.1517G>C p.R506T 7
8 COSM40794 ZNF473 central nervous system,brain,glioma,NS c.42C>T p.D14D 7
9 COSM39217 ZMYND8 central nervous system,brain,glioma,NS c.2162T>G p.V721G 7
10 COSM40504 ZMYND8 central nervous system,brain,glioma,NS c.2176G>A p.D726N 7
11 COSM39507 ZMAT4 central nervous system,brain,glioma,NS c.76G>A p.E26K 7
12 COSM39445 ZIC1 central nervous system,brain,glioma,NS c.57G>A p.A19A 7
13 COSM40870 ZFC3H1 central nervous system,brain,glioma,NS c.1055G>A p.S352N 7
14 COSM40793 ZFAT central nervous system,brain,glioma,NS c.1006G>A p.V336M 7
15 COSM40680 ZEB1 central nervous system,brain,glioma,NS c.1913C>T p.S638L 7
16 COSM41152 ZC3H6 central nervous system,brain,glioma,NS c.2254G>T p.G752* 7
17 COSM40778 ZBTB4 central nervous system,brain,glioma,NS c.2842C>T p.L948F 7
18 COSM40777 ZBTB24 central nervous system,brain,glioma,NS c.1886C>T p.P629L 7
19 COSM39508 ZBTB21 central nervous system,brain,glioma,NS c.997G>A p.G333S 7
20 COSM40776 ZBTB16 central nervous system,brain,glioma,NS c.413C>T p.A138V 7
21 COSM41039 YWHAH central nervous system,brain,glioma,NS c.169C>T p.R57* 7
22 COSM40774 YTHDC2 central nervous system,brain,glioma,NS c.782C>T p.A261V 7
23 COSM39272 XPO7 central nervous system,brain,glioma,NS c.1157G>A p.R386Q 7
24 COSM40772 XPO1 central nervous system,brain,glioma,NS c.1147G>A p.E383K 7
25 COSM21780 XAB2 central nervous system,brain,glioma,NS c.849C>A p.I283I 7
26 COSM39469 WNK2 central nervous system,brain,glioma,NS c.3757G>A p.A1253T 7
27 COSM40770 WNK1 central nervous system,brain,glioma,NS c.5293G>A p.G1765S 7
28 COSM40769 WFS1 central nervous system,brain,glioma,NS c.573G>A p.K191K 7
29 COSM40767 WEE1 central nervous system,brain,glioma,NS c.765G>A p.K255K 7
30 COSM40766 WDTC1 central nervous system,brain,glioma,NS c.1118C>T p.A373V 7
31 COSM40765 WDR70 central nervous system,brain,glioma,NS c.463G>A p.E155K 7
32 COSM40764 WDR6 central nervous system,brain,glioma,NS c.1170C>T p.F390F 7
33 COSM40761 WDR34 central nervous system,brain,glioma,NS c.1484C>T p.T495I 7
34 COSM40762 WDR34 central nervous system,brain,glioma,NS c.475G>A p.A159T 7
35 COSM39468 WDR24 central nervous system,brain,glioma,NS c.790C>T p.R264C 7
36 COSM40758 WDFY3 central nervous system,brain,glioma,NS c.1126C>T p.H376Y 7
37 COSM39888 WBP1L central nervous system,brain,glioma,NS c.490C>T p.P164S 7
38 COSM40234 WASHC4 central nervous system,brain,glioma,NS c.367+1G>A p.? 7
39 COSM40754 VPS45 central nervous system,brain,glioma,NS c.370G>A p.E124K 7
40 COSM40753 VPS41 central nervous system,brain,glioma,NS c.1830G>A p.Q610Q 7
41 COSM39977 VPS13B central nervous system,brain,glioma,NS c.1913C>T p.T638I 7
42 COSM41129 VPS13B central nervous system,brain,glioma,NS c.9845A>C p.K3282T 7
43 COSM40751 VPS13A central nervous system,brain,glioma,NS c.7400G>A p.G2467D 7
44 COSM40750 VN2R1P central nervous system,brain,glioma,NS c.1753C>T p.P585S 7
45 COSM40748 VIPR2 central nervous system,brain,glioma,NS c.598G>A p.V200M 7
46 COSM39478 VIPAS39 central nervous system,brain,glioma,NS c.1200G>C p.K400N 7
47 COSM39246 VEGFD central nervous system,brain,glioma,NS c.694A>G p.K232E 7
48 COSM40746 VDR central nervous system,brain,glioma,NS c.1135C>T p.L379F 7
49 COSM40744 VCPIP1 central nervous system,brain,glioma,NS c.3601G>A p.E1201K 7
50 COSM40745 VCL central nervous system,brain,glioma,NS c.1369C>T p.P457S 7

Copy number variations for Glioma from CNVD:

7 (show top 50) (show all 1065)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13321 2 208809197 208828051 Copy number IDH1 Glioma
2 14132 1 10403401 10408000 Deletion Glioma
3 14198 1 105227801 105232100 Deletion Glioma
4 15004 1 111800000 116100000 Deletion Glioma
5 15199 1 113411001 113417300 Deletion BC037540 Glioma
6 15250 1 113839501 113849000 Deletion Glioma
7 15641 1 117679901 117685200 Deletion Glioma
8 15695 1 118394101 118397900 Deletion Glioma
9 19119 1 148648801 148652600 Deletion Glioma
10 19806 1 151480801 151485400 Deletion Glioma
11 20843 1 154791301 154797500 Deletion IQGAP3 Glioma
12 21174 1 157132201 157138600 Deletion Glioma
13 21291 1 157913501 157918300 Deletion Glioma
14 21685 1 160317401 160321200 Deletion Glioma
15 23692 1 173061201 173070300 Deletion Glioma
16 24042 1 174742901 174746800 Deletion Glioma
17 24302 1 178448601 178452400 Deletion Glioma
18 25156 1 185029601 185033600 Deletion Glioma
19 25220 1 185729601 185734900 Deletion Glioma
20 25241 1 185980701 185991100 Deletion Glioma
21 25290 1 186804101 186808700 Deletion Glioma
22 25655 1 192615401 192619700 Deletion Glioma
23 26024 1 195765301 195771800 Deletion Glioma
24 26054 1 196268601 196275300 Deletion Glioma
25 26178 1 197703301 197708700 Deletion Glioma
26 26883 1 20368201 20372100 Deletion PLA2G2C Glioma
27 26979 1 204445801 204451500 Deletion Glioma
28 27209 1 205357001 205361800 Deletion Glioma
29 27636 1 210535701 210541200 Deletion Glioma
30 27909 1 215522601 215526900 Deletion Glioma
31 27938 1 216247201 216257200 Deletion Glioma
32 27948 1 216310301 216315100 Deletion Glioma
33 28054 1 217987801 217992100 Deletion Glioma
34 28169 1 219443901 219451100 Deletion Glioma
35 28238 1 220438701 220448900 Deletion Glioma
36 28860 1 226089101 226092600 Deletion Glioma
37 29433 1 232027401 232031900 Deletion Glioma
38 29707 1 234613701 234620000 Deletion Glioma
39 29744 1 234984301 234988400 Deletion ACTN2 Glioma
40 29950 1 238457901 238463400 Deletion Glioma
41 29974 1 238682401 238685500 Deletion Glioma
42 30033 1 239425501 239429300 Deletion Glioma
43 30273 1 241490101 241494000 Deletion Glioma
44 30527 1 244220301 244224400 Deletion Glioma
45 30564 1 244503701 244507900 Deletion Glioma
46 30805 1 246116501 246126100 Deletion OR2W3 Glioma
47 31058 1 25029301 25036000 Deletion Glioma
48 31536 1 28129101 28135200 Deletion SMPDL3B Glioma
49 31728 1 30200000 32400000 Deletion Glioma
50 33111 1 42513801 42517800 Deletion FOXJ3 Glioma

Expression for Glioma

Search GEO for disease gene expression data for Glioma.

Pathways for Glioma

Pathways related to Glioma according to GeneCards Suite gene sharing:

(show top 50) (show all 79)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 AKT3 BAX CCND1 CDK6 EGFR ERBB2
2
Show member pathways
13.48 AKT3 BAX CCND1 EGFR ERBB2 MDM2
3
Show member pathways
13.29 AKT3 BAX CCND1 EGFR ERBB2 PRKCA
4
Show member pathways
13.11 AKT3 EGFR MDM2 PRKCA PTEN TP53
5
Show member pathways
12.98 AKT3 CCND1 CDK6 EGFR ERBB2 PRKCA
6
Show member pathways
12.87 AKT3 BAX ERBB2 PRKCA PTEN TP53
7
Show member pathways
12.85 AKT3 CCND1 EGFR MMP2 PRKCA PTEN
8
Show member pathways
12.84 AKT3 CCND1 CDK6 PRKCA TP53
9
Show member pathways
12.81 AKT3 EGFR ERBB2 MDM2 PTEN TP53
10 12.75 AKT3 BAX CCND1 CDK6 EGFR MDM2
11
Show member pathways
12.68 AKT3 BAX EGFR ERBB2 MMP2 TP53
12
Show member pathways
12.63 AKT3 CCND1 CDK6 MDM2 TP53
13
Show member pathways
12.6 AKT3 EGFR ERBB2 PRKCA PTEN TP53
14
Show member pathways
12.6 AKT3 EGFR ERBB2 MDM2 PRKCA TP53
15
Show member pathways
12.59 AKT3 BAX CCND1 CDK6 EGFR ERBB2
16
Show member pathways
12.56 AKT3 BAX CCND1 ERBB2 PTEN
17
Show member pathways
12.54 AKT3 BAX EGFR ERBB2 MDM2 PRKCA
18 12.53 CCND1 CDK6 EGFR ERBB2 MDM2 PRKCA
19 12.51 AKT3 CCND1 CDK6 PRKCA TP53
20
Show member pathways
12.48 AKT3 BAX CCND1 MDM2 PTEN TP53
21 12.46 AKT3 BAX CCND1 TP53
22
Show member pathways
12.45 BAX CCND1 CDK6 MDM2 PTEN TP53
23 12.4 CCND1 CDK6 MDM2 TP53
24
Show member pathways
12.4 AKT3 CCND1 EGFR ERBB2 PRKCA
25 12.37 BAX CCND1 CDK6 MDM2 TP53
26
Show member pathways
12.35 AKT3 BAX CCND1 MDM2 PTEN TP53
27
Show member pathways
12.35 AKT3 CCND1 EGFR ERBB2 MDM2 PRKCA
28
Show member pathways
12.33 AKT3 EGFR ERBB2 PRKCA
29
Show member pathways
12.28 AKT3 EGFR PRKCA PTEN
30 12.28 BAX CCND1 EGFR MMP2 TP53
31 12.25 BAX CCND1 EGFR MDM2 PTEN TP53
32
Show member pathways
12.25 AKT3 BAX CCND1 EGFR ERBB2 MDM2
33 12.24 EGFR ERBB2 PRKCA PTEN
34
Show member pathways
12.24 AKT3 EGFR ERBB2 PRKCA PTEN
35
Show member pathways
12.18 AKT3 CCND1 EGFR MDM2 PTEN
36 12.16 BAX EGFR MDM2 MMP2 PTEN TP53
37 12.16 AKT3 BAX CCND1 MDM2 PTEN TP53
38
Show member pathways
12.13 AKT3 EGFR ERBB2 PRKCA TP53
39 12.1 AKT3 BAX PRKCA PTEN TP53
40 12.09 CCND1 EGFR PRKCA TP53
41 12.09 AKT3 CCND1 MDM2 PRKCA TP53
42
Show member pathways
12.08 AKT3 CCND1 EGFR ERBB2 MDM2 MMP2
43 12 AKT3 BAX CCND1 MMP2 PRKCA
44 11.99 AKT3 EGFR ERBB2 PRKCA
45 11.96 AKT3 BAX CCND1 CDK6 EGFR ERBB2
46 11.95 CCND1 EGFR MDM2 PTEN
47 11.93 CCND1 CDK6 MDM2 TP53
48 11.88 AKT3 BAX CCND1 CDK6 PTEN TP53
49 11.87 AKT3 MDM2 PTEN
50 11.87 AKT3 CCND1 EGFR ERBB2 MDM2 MMP2

GO Terms for Glioma

Cellular components related to Glioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.23 ACSL5 BAX IDH1 IDH2 MMP2 PRKCA

Biological processes related to Glioma according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 protein phosphorylation GO:0006468 9.99 AKT3 CCND1 CDK6 EGFR ERBB2 PRKCA
2 positive regulation of gene expression GO:0010628 9.92 CDK6 ERBB2 MDM2 PTEN TP53
3 response to organic cyclic compound GO:0014070 9.78 CCND1 EGFR IDH1 PTEN
4 positive regulation of cell growth GO:0030307 9.75 EGFR ERBB2 LGI1
5 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.72 BAX MDM2 TP53
6 cellular response to growth factor stimulus GO:0071363 9.71 EGFR ERBB2 MDM2
7 ERBB2 signaling pathway GO:0038128 9.63 EGFR ERBB2 PRKCA
8 cellular response to organic substance GO:0071310 9.61 BAX CCND1 MDM2
9 response to magnesium ion GO:0032026 9.58 CCND1 MDM2
10 response to steroid hormone GO:0048545 9.58 CCND1 IDH1 MDM2
11 negative regulation of telomerase activity GO:0051974 9.57 POT1 TP53
12 mitotic G1 DNA damage checkpoint GO:0031571 9.56 CCND1 TP53
13 phosphatidylinositol-mediated signaling GO:0048015 9.56 EGFR ERBB2 PTEN TP53
14 isocitrate metabolic process GO:0006102 9.49 IDH1 IDH2
15 response to UV-A GO:0070141 9.37 CCND1 EGFR
16 regulation of cell motility GO:2000145 9.33 CDK6 EGFR ERBB2
17 cellular response to actinomycin D GO:0072717 9.32 MDM2 TP53
18 cell proliferation GO:0008283 9.1 BAX EGFR ERBB2 LGI1 PTEN TP53
19 glyoxylate cycle GO:0006097 8.96 IDH1 IDH2

Molecular functions related to Glioma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.91 BAX EGFR ERBB2 MDM2 PTEN TP53
2 kinase activity GO:0016301 9.8 AKT3 CCND1 CDK6 EGFR ERBB2 PRKCA
3 protein kinase activity GO:0004672 9.73 AKT3 CCND1 CDK6 EGFR ERBB2 PRKCA
4 protein phosphatase binding GO:0019903 9.54 EGFR ERBB2 TP53
5 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.4 EGFR ERBB2
6 isocitrate dehydrogenase (NADP+) activity GO:0004450 9.16 IDH1 IDH2
7 enzyme binding GO:0019899 9.1 CCND1 EGFR MDM2 PRKCA PTEN TP53
8 isocitrate dehydrogenase activity GO:0004448 8.96 IDH1 IDH2

Sources for Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....